A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.
about
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerBispecific digoxigenin-binding antibodies for targeted payload deliveryAn alternative chemical redox method for the production of bispecific antibodies: implication in rapid detection of food borne pathogensContribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma TreatmentsA novel redox method for rapid production of functional bi-specific antibodies for use in early pilot studiesSmall is beautiful: insulin-like growth factors and their role in growth, development, and cancerSingle variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies.Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal modelsA modular IgG-scFv bispecific antibody topology.Stability engineering of scFvs for the development of bispecific and multivalent antibodies.Next generation of antibody therapy for cancer.A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approachMultiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemiasDual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma.Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activityEarly drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials.A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activityCombining targeted therapies: practical issues to consider at the bench and bedside.Role of IGF-1 receptor in radiation response.Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing.Role of insulin-like growth factor-1R system in colorectal carcinogenesisThe new paradigm in the treatment of colorectal cancer: are we hitting the right target?Monoclonal antibody-based therapeutics for leukemia.Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignanciesInsulin-like growth factor: current concepts and new developments in cancer therapy.Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancerThe potential role of nanotechnology in therapeutic approaches for triple negative breast cancer.Interaction of antibodies with ErbB receptor extracellular regions.Novel targets in esophageal and gastric cancer: beyond antiangiogenesis.Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling.Bispecific antibodies for cancer therapy.Research and development of next generation of antibody-based therapeuticsHepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma.Dual targeting strategies with bispecific antibodies.Targeted therapy in nonmelanoma skin cancers.Novel methods of targeted drug delivery: the potential of multifunctional nanoparticles.Recent progress in protein-protein interaction study for EGFR-targeted therapeutics.A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.
P2860
Q26852215-782812DF-AFF4-488B-88ED-D95074DCE6BDQ27667652-BA584A1D-AC5D-4B60-95F9-0B57047C99C7Q28540976-C34AB0D2-A054-4592-83C9-D8E3A947E50AQ28547357-9A13087A-A1D6-4FAE-ABDE-92DF3014C0F5Q28742330-93E57163-6E56-4E01-884A-957CC353D877Q30395770-E7802A67-4B68-47C3-9589-761770BB13E6Q33234057-C2466343-319B-4527-9E75-18C571598F65Q33293219-F368D7D7-2F1F-490C-9DBA-91360133313AQ33519465-4034353C-7035-479E-9203-AB1CF4335759Q33574335-75A594B6-1D0A-405A-A292-A1BF10B5B85BQ33579636-6E57FCAA-7B94-46ED-8E5A-362CF8807B9BQ33846405-B25E99D9-92A0-440C-8D1B-54792ABAD155Q33925323-208815F1-E5D3-47CE-ADC1-C23B4C5C40D6Q34369841-E721BA70-EEB3-41DA-9582-E247D4C93122Q34442002-56E0566B-B5DD-4295-B18F-C499FE8BFFF9Q34575855-88C53A3F-D464-4AEF-947E-6BEDAAF4CC1BQ35006620-D889115F-A35F-4A57-9FFF-E064186B8E22Q35146077-DF54DFD7-D13E-47DB-98FD-B8E8D572CE73Q35583672-7A4FBE3F-2FE6-40C6-8CA8-B232610292E3Q35762239-DF655866-81B7-4038-8BAC-DAA95E9DFFAAQ36254477-3EB6C141-5772-42F6-A0A5-ED4CC9203911Q36642456-3F7CD691-AA82-4590-8A54-7F60024201D0Q36736346-DA4608EE-2A8E-47E3-B23E-C242317283C3Q36739759-C2E3D0B9-9B9C-472A-BFCC-7617D13072B9Q36812355-C43829DA-4DAB-43A0-8636-BD50A204FE7AQ37047067-EB04E6A3-C0FE-4656-863B-C6D578775647Q37113552-62FB7C6A-B0AB-4B3B-86E9-3B99050510C5Q37138970-35C7D1F5-FEFF-4DEF-92C3-A73227B93323Q37304764-89D3C97E-8581-4A67-BC60-86103BE047E5Q37320814-74B374F8-8BCD-464D-9094-075441597A8EQ37566645-70D6C46C-B5DD-458B-909C-BB32FC8FFDECQ37588787-0C56BDF4-F9EB-4F05-AB08-4137FBC14967Q37773263-8C90F9DB-1F10-4DB5-AEFA-4AACC3899865Q37778732-24B8EAA7-3AC9-4E82-B3EE-66B307703584Q37821305-06A87A3B-35CF-4032-B268-480AE7D6C716Q37997559-8DBDC5B2-407D-41D1-8749-A05BAAE16E57Q38161358-E4B4DA82-EA29-4FC5-8B3A-FE4B9510EDB6Q38177370-301BF264-A2DD-47AE-ADB6-3644BD98FB7AQ38899428-1D4F12CC-22A5-4D96-B0BE-F1A311A8FD30Q39133025-71F140D0-95F1-46ED-9589-3A8719CA5A87
P2860
A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
A fully human recombinant IgG- ...... r enhanced antitumor activity.
@en
type
label
A fully human recombinant IgG- ...... r enhanced antitumor activity.
@en
prefLabel
A fully human recombinant IgG- ...... r enhanced antitumor activity.
@en
P2093
P2860
P356
P1476
A fully human recombinant IgG- ...... r enhanced antitumor activity.
@en
P2093
Dale L Ludwig
Daniel J Hicklin
Deborah Anselma
Dipa Patel
Eric Corcoran
Haifan Zhang
James Tonra
Larry Witte
P2860
P304
19665-19672
P356
10.1074/JBC.M500815200
P407
P577
2005-03-09T00:00:00Z